MX374724B - Derivados de carbazol. - Google Patents

Derivados de carbazol.

Info

Publication number
MX374724B
MX374724B MX2017005255A MX2017005255A MX374724B MX 374724 B MX374724 B MX 374724B MX 2017005255 A MX2017005255 A MX 2017005255A MX 2017005255 A MX2017005255 A MX 2017005255A MX 374724 B MX374724 B MX 374724B
Authority
MX
Mexico
Prior art keywords
compounds
disclosed
carbazole derivatives
formula
diseases
Prior art date
Application number
MX2017005255A
Other languages
English (en)
Spanish (es)
Other versions
MX2017005255A (es
Inventor
Douglas G Batt
John E Macor
Joseph A Tino
Qingjie Liu
Saleem Ahmad
Satheesh Kesavan Nair
Scott Hunter Watterson
Tarun Kumar Maishal
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX374724(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2017005255A publication Critical patent/MX2017005255A/es
Publication of MX374724B publication Critical patent/MX374724B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2017005255A 2014-10-24 2015-10-23 Derivados de carbazol. MX374724B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068234P 2014-10-24 2014-10-24
PCT/US2015/057077 WO2016065236A1 (en) 2014-10-24 2015-10-23 Carbazole derivatives

Publications (2)

Publication Number Publication Date
MX2017005255A MX2017005255A (es) 2017-08-18
MX374724B true MX374724B (es) 2025-03-06

Family

ID=54427879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005255A MX374724B (es) 2014-10-24 2015-10-23 Derivados de carbazol.

Country Status (34)

Country Link
US (3) US10266491B2 (cg-RX-API-DMAC7.html)
EP (1) EP3209651B9 (cg-RX-API-DMAC7.html)
JP (1) JP6599983B2 (cg-RX-API-DMAC7.html)
KR (1) KR102514914B1 (cg-RX-API-DMAC7.html)
CN (1) CN107074804B (cg-RX-API-DMAC7.html)
AR (1) AR102427A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015335703B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017007545A2 (cg-RX-API-DMAC7.html)
CA (1) CA2965523A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017001001A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017004517A2 (cg-RX-API-DMAC7.html)
CY (1) CY1122549T1 (cg-RX-API-DMAC7.html)
DK (1) DK3209651T3 (cg-RX-API-DMAC7.html)
EA (1) EA032361B1 (cg-RX-API-DMAC7.html)
ES (1) ES2761903T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20192197T2 (cg-RX-API-DMAC7.html)
HU (1) HUE048321T2 (cg-RX-API-DMAC7.html)
IL (1) IL251798B (cg-RX-API-DMAC7.html)
LT (1) LT3209651T (cg-RX-API-DMAC7.html)
MA (1) MA40302B1 (cg-RX-API-DMAC7.html)
ME (1) ME03754B (cg-RX-API-DMAC7.html)
MX (1) MX374724B (cg-RX-API-DMAC7.html)
MY (1) MY190568A (cg-RX-API-DMAC7.html)
PE (1) PE20171239A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500724B1 (cg-RX-API-DMAC7.html)
PL (1) PL3209651T3 (cg-RX-API-DMAC7.html)
PT (1) PT3209651T (cg-RX-API-DMAC7.html)
RS (1) RS59707B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201903619YA (cg-RX-API-DMAC7.html)
SI (1) SI3209651T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000035T1 (cg-RX-API-DMAC7.html)
TN (1) TN2017000158A1 (cg-RX-API-DMAC7.html)
TW (1) TWI676618B (cg-RX-API-DMAC7.html)
WO (1) WO2016065236A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53568A (fr) 2014-10-24 2022-02-23 Takeda Pharmaceuticals Co Médicaments pour le traitement de maladies ophtalmiques
ES2800173T3 (es) * 2014-10-24 2020-12-28 Bristol Myers Squibb Co Compuestos de atropisómeros tricíclicos
KR102327917B1 (ko) * 2016-07-07 2021-11-17 주식회사 대웅제약 신규한 4-아미노피라졸로[3,4-d]피리미디닐아자바이사이클로 유도체 및 이를 포함하는 약학 조성물
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
WO2019075386A1 (en) 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
CN109053542A (zh) * 2018-07-25 2018-12-21 南通大学 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法
EP4038059B1 (en) * 2019-10-04 2023-09-20 Bristol-Myers Squibb Company Substituted carbazole compounds
CN110862396B (zh) * 2019-11-29 2021-06-04 浙江工业大学 一种吡咯并[3,4-c]咔唑-1,3(2H,6H)-二酮类化合物的合成方法
US20220009920A1 (en) * 2020-04-10 2022-01-13 Gb005, Inc. Kinase inhibitors
US12448363B2 (en) 2020-06-02 2025-10-21 Vidya Therapeutics, Inc. Kinase inhibitors
CN115232061B (zh) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 一种3-硝基-9-乙基咔唑粗产物的提取工艺
KR20250034121A (ko) * 2022-07-06 2025-03-10 비비디온 테라퓨틱스, 인코포레이티드 Wrn 헬리케이스 억제제를 포함하는 약제학적 조성물
CA3268880A1 (en) * 2022-09-29 2024-04-04 Vividion Therapeutics, Inc. N-ACRYLOYLMORPHOLINE DERIVATIVES USED AS KEAP1 MODULATORS AND RELATED USES

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
KR20070119606A (ko) 2004-11-10 2007-12-20 씨지아이 파마슈티칼스, 인크. 특정 이미다조[1,2-a]피라진-8-일아민, 그의 제조 방법및 용도
AU2005315319B2 (en) 2004-12-17 2011-07-07 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8518964B2 (en) * 2005-11-22 2013-08-27 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
CA2663178C (en) 2006-09-11 2016-01-12 Matrix Laboratories Ltd. Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2707491A1 (en) 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
PT2247558T (pt) 2008-02-14 2022-03-21 Lilly Co Eli Novos agentes de imagiologia para deteção de disfunção neurológica
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
EP2307377A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
CN102325753B (zh) 2008-12-19 2014-09-10 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
ES2733093T3 (es) 2009-02-13 2019-11-27 Nextivity Inc Control remoto para amplificador
EP2582668B1 (en) 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
AU2011330850B2 (en) 2010-11-15 2016-01-28 Viiv Healthcare Uk Limited Inhibitors of HIV replication
PH12013502379A1 (en) 2011-05-17 2014-01-13 Hoffmann La Roche Inhibitors of bruton's tyrosine kinase
HK1209632A1 (en) 2012-01-10 2016-04-08 林伯士艾瑞斯公司 Irak inhibitors and uses thereof
KR20150060839A (ko) 2012-10-26 2015-06-03 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
UY35625A (es) * 2013-06-25 2014-12-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
EP3013815B1 (en) * 2013-06-25 2017-05-03 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
HUE050706T2 (hu) 2014-10-24 2020-12-28 Bristol Myers Squibb Co Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként
ES2800173T3 (es) * 2014-10-24 2020-12-28 Bristol Myers Squibb Co Compuestos de atropisómeros tricíclicos

Also Published As

Publication number Publication date
KR102514914B1 (ko) 2023-03-27
CA2965523A1 (en) 2016-04-28
JP6599983B2 (ja) 2019-10-30
AU2015335703A1 (en) 2017-06-08
CO2017004517A2 (es) 2017-08-31
PE20171239A1 (es) 2017-08-24
US10266491B2 (en) 2019-04-23
CN107074804A (zh) 2017-08-18
IL251798B (en) 2020-08-31
HUE048321T2 (hu) 2020-07-28
EP3209651B9 (en) 2020-05-20
SG11201703187PA (en) 2017-05-30
KR20170075756A (ko) 2017-07-03
EP3209651B1 (en) 2019-10-23
AR102427A1 (es) 2017-03-01
PH12017500724A1 (en) 2017-10-09
MY190568A (en) 2022-04-27
AU2015335703B2 (en) 2020-05-21
ES2761903T3 (es) 2020-05-21
US20200255377A1 (en) 2020-08-13
PH12017500724B1 (en) 2023-07-05
EA032361B1 (ru) 2019-05-31
US10676434B2 (en) 2020-06-09
SG10201903619YA (en) 2019-05-30
TW201629014A (zh) 2016-08-16
MA40302A1 (fr) 2018-05-31
RS59707B1 (sr) 2020-01-31
CY1122549T1 (el) 2021-01-27
HRP20192197T1 (hr) 2020-03-06
EP3209651A1 (en) 2017-08-30
HRP20192197T8 (hr) 2020-04-03
WO2016065236A1 (en) 2016-04-28
HRP20192197T2 (hr) 2020-11-13
MA40302B1 (fr) 2018-10-31
SI3209651T1 (sl) 2019-12-31
DK3209651T3 (da) 2020-02-03
US20190225583A1 (en) 2019-07-25
LT3209651T (lt) 2020-01-10
CN107074804B (zh) 2020-02-18
CL2017001001A1 (es) 2017-11-24
TWI676618B (zh) 2019-11-11
TN2017000158A1 (en) 2018-10-19
BR112017007545A2 (pt) 2017-12-19
PT3209651T (pt) 2019-12-30
ME03754B (me) 2021-04-20
JP2017535536A (ja) 2017-11-30
IL251798A0 (en) 2017-06-29
MX2017005255A (es) 2017-08-18
US11053197B2 (en) 2021-07-06
EA201790745A1 (ru) 2017-08-31
US20170362176A1 (en) 2017-12-21
SMT202000035T1 (it) 2020-03-13
PL3209651T3 (pl) 2020-03-31

Similar Documents

Publication Publication Date Title
MX374724B (es) Derivados de carbazol.
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
CL2019001674A1 (es) Inhibidores de imidazopirazina de tirosina quinasa de bruton.
MX2022002976A (es) Inhibidores selectivos de jak1.
MX2023000812A (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
MX2018002520A (es) Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo.
MX387097B (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
UY35369A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
MX369217B (es) Compuesto de triazina y su uso para propositos medicos.
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
MX2019013308A (es) Composiciones y compuestos terapeuticos, y metodos para su uso.
MX2018004664A (es) Antagonistas de ep4.
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
ECSP18056196A (es) Derivados de indano
MX2019000159A (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa.
TH178640A (th) อนุพันธ์คาร์บาโซล

Legal Events

Date Code Title Description
FG Grant or registration